Call Us: 1.800.873.5297

By

FDA Issues Class I Recall for Specific Lots of Bard LifeStent® Solo Vascular Stents due to Failure to Deploy

On September 30, 2013, the FDA issued a Class I Recall for LifeStent® Solo Vascular Stent products manufactured and distributed from November 2011 to June 13, 2012. The FDA adds that “[c]lass I recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of these […]

By

FDA Investigates Serious Adverse Events Reported by Patients taking Lukemia Drug Iclusig™

On October 11, 2013, the FDA issued a Drug Safety Communication informing the public that the FDA “is investigating an increasing frequency of reports of serious and life-threatening blood clots and severe narrowing of blood vessels (arteries and veins) of patients taking the leukemia chemotherapy drug Iclusig™ (ponatinib).” According to Reuters, Iclusig™ was approved by […]

By

EPA Begins Radiation Testing on Barrier Trench at Bridgeton Landfill; Activists Say This Isn’t Enough

According to The Associated Press, initial testing is underway on a trench at the Bridgeton Landfill. The trench is supposed to help prevent an underground fire at Bridgeton reaching from World War II-era nuclear waste buried 1,200 feet away (less than a quarter mile) at West Lake Landfill. Before the trench can be dug, the […]

By

Incretin-Based Diabetes Drug Lawsuits Allege Increased Risk of Pancreatic Cancer

In August 2013, the United States Judicial Panel on Multidistrict Litigation (JPML) decided to consolidate all incretin-based diabetes drug lawsuits filed in federal court – including Januvia®, Janumet®, Victoza®, and Byetta® – into a centralized Multidistrict Litigation (MDL 2452). All federally filed incretin-based diabetes drug cases have been consolidated in the United States District Court […]

By

Plaintiffs Make Another Attempt to Consolidate Lipitor® Cases in a Federal MDL

On August 8, 2013, plaintiffs’ motion to consolidate all federally filed Lipitor® cases into a central Multidistrict Litigation (MDL) was denied by the Judicial Panel on Multidistrict Litigation (JPML). The basis for the JPML’s denial of centralization was that too few Lipitor lawsuits were on file in federal court. However, another motion to consolidate all […]

By

FDA Warns that Some Antibiotics Linked to Permanent Nerve Damage

Recently, the United States Food and Drug Administration (FDA) issued a warning that fluoroquinolone antibiotics, taken by mouth or injection, carry a serious risk for permanent peripheral neuropathy. As a result, the FDA is requiring manufacturers of these antibiotics to revise their labels and medication guides to warn people of this dangerous health risk. Fluoroquinolones are among the […]

By

NuvaRing® MDL Update: Number of NuvaRing® Lawsuits Filed in Federal Court Continue to Grow

There are currently over 1,340 NuvaRing® cases pending against the manufacturers of NuvaRing®, and the number of cases filed against the manufacturers of NuvaRing® continue to increase. Since August, 61 new cases have been filed in federal court. All cases filed in federal court are consolidated in the Multidistrict Litigation In re: NuvaRing® Products Liability […]

By

Over 1,400 Lawsuits Pending in Federal Court Against Manufacturers of Pradaxa®

Since August, 79 lawsuits have been filed in federal court against the manufacturers of Pradaxa®. These lawsuits have been added to the Multidistrict Litigation In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385), which is currently pending in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge […]

By

Mirena® IUD Lawsuit Update: 36 New Lawsuits Filed in Federal Multidistrict Litigation (MDL 2434)

The number of Mirena® lawsuits continues to grow with 159 lawsuits currently on file in federal court in the Multidistrict Litigation In re: Mirena® IUD Products Liability Litigation (MDL 2434), according to the most recent report issued by the Judicial Panel on Multidistrict Litigation (JPML). The Mirena® MDL is pending in the United States District Court for […]

By

Transvaginal Mesh Lawsuit Update: Over 31,000 Transvaginal Mesh Lawsuits On File in Federal Court

As of now, over 31,000 transvaginal mesh lawsuits are currently pending in federal courts – and the number of cases continues to grow. According to the most recent report released by the Judicial Panel on Multidistrict Litigation (JPML), there are six multidistrict litigations involving different transvaginal mesh device manufacturers where approximately 31,170 lawsuits are pending. Since August, […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.